Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results. Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to ...

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including more than $200 million in upfront and near-term milestone payments.

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills. Novo’s weight-loss drugs are administered by injection and a pill version would be more convenient for patients, ...

Septerna may receive up to $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments. The collaboration targets four GPCR programs, including GLP-1 ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it trades over a 20% discount.

Novo Nordisk said Wednesday that it will work with the biotech Septerna to develop oral GLP-1 obesity drugs, as it races to catch up to competitor Eli Lilly’s efforts to bring a more convenient ...

3 Key Takeaways . Novo Nordisk and Septerna have entered a global collaboration to develop oral small molecule therapies for obesity, type 2 diabetes, and other cardiometabolic diseases, initially ...

Danish pharmaceutical company Novo Nordisk has signed a collaboration deal with U.S. biotech Septerna that will see the two companies develop pills to treat obesity, type 2 diabetes and other ...